Joerg Gruber, Chairman
Mr. Gruber is a founder of Tarix and has served as its Chairman since April 2007. He co-founded Clubb Capital Limited, a London-based corporate finance and venture capital firm with a focus on healthcare, in 1995 and has been its Chairman since 1999. From 1990 to 1995, Mr. Gruber was an independent venture capital consultant. Prior to his career in venture capital, Mr. Gruber spent 14 years in Banking and Investment Banking at UBS, Goldman Sachs and Lehman Brothers. Mr. Gruber is the Chairman of Pathfinder Cell Therapy, Inc., a public company focused on developing a novel cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage.
Richard Franklin, M.D., Ph.D., Director and CEO
Dr Franklin is a founder of Tarix and has served as its President and CEO since its inception. He is Chief Executive of Pathfinder Cell Therapy, Inc. a public company focused on developing a novel cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage, and a director of Raptor Pharmaceuticals.
Gere diZerega M.D. Medical Director
Dr. diZerega has served as Medical Director since April 2007. He is Medical Director of Synthemed, Inc. Dr. diZerega is Professor, Department of Obstetrics and Gynecology at Women’s Hospital, University of Southern California Medical Center and his areas of research include post-operative adhesions, peritoneal healing and post-surgical wound repair. Dr. diZerega is co-inventor of TXA127.
Management and Board
Joerg Gruber, Chairman
Mr. Gruber is a founder of Tarix and has served as its Chairman since April 2007. He co-founded Clubb Capital Limited, a London-based corporate finance and venture capital firm with a focus on healthcare, in 1995 and has been its Chairman since 1999. From 1990 to 1995, Mr. Gruber was an independent venture capital consultant. Prior to his career in venture capital, Mr. Gruber spent 14 years in Banking and Investment Banking at UBS, Goldman Sachs and Lehman Brothers. Mr. Gruber is the Chairman of Pathfinder Cell Therapy, Inc., a public company focused on developing a novel cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage.
Richard Franklin, M.D., Ph.D., Director and CEO
Dr Franklin is a founder of Tarix and has served as its President and CEO since its inception. He is Chief Executive of Pathfinder Cell Therapy, Inc. a public company focused on developing a novel cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage, and a director of Raptor Pharmaceuticals.
Gere diZerega M.D. Medical Director
Dr. diZerega has served as Medical Director since April 2007. He is Medical Director of Synthemed, Inc. Dr. diZerega is Professor, Department of Obstetrics and Gynecology at Women’s Hospital, University of Southern California Medical Center and his areas of research include post-operative adhesions, peritoneal healing and post-surgical wound repair. Dr. diZerega is co-inventor of TXA127.